The National Institute of Allergy and Infectious Diseases has awarded a 7-year, $9.8 million grant to develop an AIDS vaccine to four Seattle-based research organizations and Rockefeller University.
The nonprofit Seattle Biomedical Research Institute will lead the research team, which will be made up of researchers from the University of Washington, Fred Hutchinson Cancer Research Center, Seattle Children’s Hospital and Rockefeller University in New York.
The initial 7-year grant will fund the first phase of the project, including the optimization and preclinical evaluation of two vaccine candidates. The vaccine will be designed to elicit broadly neutralizing antibodies against HIV-1. The second phase of the project will include the production of these vaccines and the evaluation of their safety and ability to provoke an immune response in a Phase I clinical trial.